May 1, 2015

Nemaura Medical to Present Positive Interim Clinical Trial Results of its sugarBEAT® System at the Marcum Microcap Conference, New York

Nemaura Medical Inc. (OTC BB: NMRD),(“Nemaura”), a medical device company developing the sugarBEAT® CGM System as a non-invasive, wireless continuous glucose monitoring system, announced today that it has conducted an interim analysis of clinical data from its ongoing 540 patient day clinical program of Type I and Type II diabetic Patients. Nemaura will present these findings at the Marcum Microcap Conference in New York on Thursday 28th May 2015.

The data will be presented by Nemaura’s CEO Dr. Faz Chowdhury as part of the Company’s presentation on its business development and commercialization strategy. Nemaura confirmed that the results of the interim analysis incorporates a 100-patient day study, involving 30 patients returning on 3 or 4 days, wearing the sugarBEAT® device for a period of 12 or 14 hours per day; the data shows comparable results to some currently marketed invasive CGM devices, with clinical accuracy in the Clarke error grid Zones A and B exceeding 95%.


Dr. Faz Chowdhury commented,

“A continuous glucose monitoring system that is minimally invasive, safe, accurate and user-friendly is an important clinical tool for maintaining glucose control in diabetic patients.”


Nemaura’s interim analysis has indicated that its primary endpoint of accuracy, and secondary endpoint of safety have been met.


About Nemaura Medical, Inc.

Nemaura Medical is developing the sugarBEAT® System as a minimally-invasive, wireless, continuous glucose monitoring system for use as an adjunct device for blood glucose monitoring. Further opportunity may exist for use of the device in intensive care hospital settings, where continuous glucose monitoring is critical.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts, and may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements.

Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Nemaura’s ongoing studies, including the safety and efficacy of Nemaura’s sugarBEAT® CGM System, the failure of future development and preliminary marketing efforts, Nemaura’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura and its partners’ ability to develop, market and sell the sugarBEAT® System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its sugarBEAT® System.

These and other risks and uncertainties are identified and described in more detail in Nemaura’s filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the current year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Nemaura undertakes no obligation to publicly update or revise any forward-looking statements.